Comparing netarsudil and brimonidine for treating normal tension glaucoma patients on latanoprost
Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%
This study is testing whether a new eye drop called netarsudil works better than brimonidine for lowering eye pressure in people with normal tension glaucoma who are already using another eye drop called latanoprost.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Westlake Eye Specialists Academic / other |
| Locations | 4 sites (Austin, Texas and 3 other locations) |
| Trial ID | NCT06449352 on ClinicalTrials.gov |
What this trial studies
This study is a randomized, multicenter, investigator-masked trial that aims to evaluate the effects of netarsudil 0.02% compared to brimonidine 0.1% on intraocular pressure (IOP) in patients with normal tension glaucoma who are currently on latanoprost 0.005% monotherapy. Participants will undergo a screening visit followed by one follow-up visit, during which clinical evaluations will include assessments of visual acuity and IOP. The goal is to determine which treatment is more effective in managing IOP in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with normal tension glaucoma who have been on latanoprost monotherapy for at least six weeks.
Not a fit: Patients with angle closure glaucoma, secondary forms of glaucoma, or those who have undergone incisional surgery for glaucoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into more effective treatment options for managing intraocular pressure in patients with normal tension glaucoma.
How similar studies have performed: Other studies have explored treatments for glaucoma, but this specific comparison of netarsudil and brimonidine in normal tension glaucoma patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18 years and older * Diagnosed with normal tension glaucoma based on the following: * IOP ≤ 21mmHg * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year * Open angles assessed by gonioscopy * Have been on latanoprost monotherapy for at least 6 weeks Exclusion Criteria: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Other forms of secondary glaucoma. * Patients with abnormal anterior segment examination other than cataract will be excluded from the study. * Patients who have had incisional surgery for glaucoma (eg: MIGs). * Patients with refractory CME or CME persisting 3 months or more. * Children, cognitive impaired and critically ill subjects will not be enrolled. * Central Corneal Thickness (CCT) ≤ 500. * Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil. * Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study. The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.
Where this trial is running
Austin, Texas and 3 other locations
- Westlake Eye Specialists - Austin Office — Austin, Texas, United States (Recruiting)
- Westlake Eye Specialists - Killeen Office — Killeen, Texas, United States (Recruiting)
- Westlake Eye Specialists - Kyle Office — Kyle, Texas, United States (Recruiting)
- Westlake Eye Specialists - New Braunfels Office — New Braunfels, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Zarmeena Vendal, MD — Westlake Eye Specialists
- Study coordinator: Zarmeena Vendal, MD
- Email: zvendal@westlakeeyes.com
- Phone: 512-472-4011
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.